Stryker Shares Outstanding 2006-2018 | SYK
Stryker shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Stryker shares outstanding for the quarter ending September 30, 2018 were 0.380B, a 0% increase year-over-year.
- Stryker 2017 shares outstanding were 0.38B, a 0.42% increase from 2016.
- Stryker 2016 shares outstanding were 0.379B, a 0.63% decline from 2015.
- Stryker 2015 shares outstanding were 0.381B, a 0.5% decline from 2014.
| Stryker Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2017 | 380 |
| 2016 | 379 |
| 2015 | 381 |
| 2014 | 383 |
| 2013 | 382 |
| 2012 | 383 |
| 2011 | 390 |
| 2010 | 400 |
| 2009 | 399 |
| 2008 | 414 |
| 2007 | 417 |
| 2006 | 412 |
| 2005 | 411 |
| Stryker Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| Q3 2018 | 380 |
| Q2 2018 | 380 |
| Q1 2018 | 381 |
| Q4 2017 | 380 |
| Q3 2017 | 380 |
| Q2 2017 | 380 |
| Q1 2017 | 379 |
| Q4 2016 | 379 |
| Q3 2016 | 379 |
| Q2 2016 | 379 |
| Q1 2016 | 377 |
| Q4 2015 | 381 |
| Q3 2015 | 381 |
| Q2 2015 | 381 |
| Q1 2015 | 384 |
| Q4 2014 | 383 |
| Q3 2014 | 383 |
| Q2 2014 | 383 |
| Q1 2014 | 383 |
| Q4 2013 | 382 |
| Q3 2013 | 382 |
| Q2 2013 | 381 |
| Q1 2013 | 383 |
| Q4 2012 | 383 |
| Q3 2012 | 383 |
| Q2 2012 | 383 |
| Q1 2012 | 384 |
| Q4 2011 | 390 |
| Q3 2011 | 388 |
| Q2 2011 | 392 |
| Q1 2011 | 394 |
| Q4 2010 | 400 |
| Q3 2010 | 398 |
| Q2 2010 | 399 |
| Q1 2010 | 400 |
| Q4 2009 | 399 |
| Q3 2009 | 400 |
| Q2 2009 | 399 |
| Q1 2009 | 399 |
| Q4 2008 | 414 |
| Q3 2008 | 416 |
| Q2 2008 | 418 |
| Q1 2008 | 418 |
| Q4 2007 | 417 |
| Q3 2007 | 418 |
| Q2 2007 | 417 |
| Q1 2007 | 416 |
| Q4 2006 | 412 |
| Q3 2006 | 412 |
| Q2 2006 | 411 |
| Q1 2006 | 411 |
| Q4 2005 | 411 |
| Q3 2005 | 411 |
| Q2 2005 | 411 |
| Q1 2005 | 411 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $64.588B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $128.543B | 19.22 |
| Abbott Laboratories (ABT) | United States | $127.387B | 25.81 |
| Boston Scientific (BSX) | United States | $51.339B | 25.94 |
| Baxter (BAX) | United States | $35.653B | 23.02 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.039B | 14.94 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.882B | 0.00 |
| ResMed (RMD) | United States | $16.410B | 31.29 |
| Perrigo (PRGO) | Ireland | $7.997B | 12.14 |
| Bio-Rad Laboratories (BIO) | United States | $7.618B | 48.71 |
| Canopy Growth (CGC) | Canada | $7.436B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.496B | 20.32 |
| Aurora Cannabis (ACB) | Canada | $6.099B | 32.21 |
| Haemonetics (HAE) | United States | $5.365B | 47.18 |
| Insulet (PODD) | United States | $4.925B | 0.00 |
| ICU Medical (ICUI) | United States | $4.805B | 26.77 |
| Hutchison China MediTech (HCM) | China | $4.419B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.779B | 0.00 |
| Neogen (NEOG) | United States | $3.367B | 50.98 |
| Agios Pharmaceuticals (AGIO) | United States | $3.261B | 0.00 |
| NuVasive (NUVA) | United States | $2.912B | 27.09 |
| National Vision Holdings (EYE) | United States | $2.458B | 47.55 |
| Quidel (QDEL) | United States | $2.024B | 26.39 |
| NxStage Medical (NXTM) | United States | $1.918B | 0.00 |
| Aphria (APHA) | $1.451B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.321B | 18.70 |
| AtriCure (ATRC) | United States | $1.188B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.021B | 1469.50 |
| VAREX IMAGING (VREX) | United States | $0.937B | 18.76 |
| PetIQ (PETQ) | United States | $0.858B | 22.23 |
| Surmodics (SRDX) | United States | $0.786B | 119.80 |
| Cerus (CERS) | United States | $0.780B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.778B | 24.78 |
| OraSure Technologies (OSUR) | United States | $0.747B | 42.07 |
| Omeros (OMER) | United States | $0.703B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.670B | 20.75 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.661B | 21.21 |
| MacroGenics (MGNX) | United States | $0.605B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.536B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.514B | 25.24 |
| Quanterix (QTRX) | United States | $0.438B | 0.00 |
| Owens & Minor (OMI) | United States | $0.428B | 4.84 |
| TG Therapeutics (TGTX) | United States | $0.423B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.376B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.331B | 21.40 |
| Evolus (EOLS) | United States | $0.327B | 0.00 |
| VAPOTHERM INC (VAPO) | United States | $0.307B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.282B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.241B | 0.00 |
| Surface Oncology (SURF) | United States | $0.238B | 0.00 |
| Bovie Medical (BVX) | United States | $0.236B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.222B | 300.25 |
| Rockwell Medical (RMTI) | United States | $0.182B | 0.00 |
| Chimerix (CMRX) | United States | $0.172B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.142B | 0.00 |
| Fonar (FONR) | United States | $0.136B | 6.83 |
| Chembio Diagnostics (CEMI) | United States | $0.106B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 16.81 |
| Female Health (VERU) | United States | $0.079B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.070B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.068B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.065B | 17.93 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.049B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Neurotrope (NTRP) | United States | $0.030B | 0.00 |
| Myomo (MYO) | United States | $0.023B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.019B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.017B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.016B | 0.00 |
| Senestech (SNES) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
